Candel Therapeutics Appoints Charles Schoch as Permanent CFO, Effective June 20, 2025

Candel Therapeutics, Inc.

Charles Schoch, interim CFO since Jan 2024, promoted to permanent CFO; base salary increased to $440,000, target bonus 40%.
Granted option to purchase 50,000 shares; 25% vests at one year, then ratably over 36 months.
Schoch previously served as VP Finance and Corporate Controller; led capital raise of ~$86M in Q4 2024.
Press release highlights upcoming BLA submission for CAN-2409 in localized prostate cancer.
No family relationships or arrangements with other parties disclosed.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Charles Schoch

Chief Financial Officer

CADL · Candel Therapeutics, Inc.

Effective: 2025-06-20
Filed: Jun 23, 2025 23:59 UTC

On June 20, 2025, the board of directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) unanimously appointed Charles Schoch as the Company’s Chief Financial Officer, effective June 20, 2025

Source: SEC EDGAR

accession 0001193125-25-144204

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.